Brain Metastases from Ovarian Carcinoma

Abstract

This paper will focus on knowledge related to brain metastases from ovarian carcinoma. So far, less than 600 cases were documented in the literature with an incidence among ovarian carcinoma patients ranging from 0.29% to 11.6%. The ovarian carcinoma was usually an advanced-stage epithelial serous carcinoma, and the median interval between diagnosis of ovarian carcinoma and brain metastases was 2 years. Most often, brain metastases, affected the cerebrum, were multiple and part of a disseminated disease. Treatment of brain metastasis has evolved over the years from whole brain radiotherapy (WBRT) only to multimodal therapy including surgical resection or stereotactic radiosurgery followed by WBRT and/or chemotherapy. The median survival after diagnosis of brain metastases was 6 months; nevertheless, a significantly better survival was achieved with multimodal therapy compared to WBRT only. It is suggested that brain imaging studies should be included in the followup of patients after treatment for ovarian carcinoma.

Brain Metastases in a Patient with Ovarian Cancer

“…[9] In 2011, Piura E and piura B reported 521 cases between 1978 and 2011. [10], while in 2014, Pakneshan et al reported 591 cases between 1978 and 2013. [11] Piura and Piura determined the incidence of brain metastases from ovarian cancer to be 1.2% [10], which was twice the incidence associated with cervical [12] or endometrial cancer [13].…”

“…[10], while in 2014, Pakneshan et al reported 591 cases between 1978 and 2013. [11] Piura and Piura determined the incidence of brain metastases from ovarian cancer to be 1.2% [10], which was twice the incidence associated with cervical [12] or endometrial cancer [13]. Pakneshan et al reported that the incidence among the various studies ranged from 0.49 to 11.4%, with an average of 2.55% [11].…”

“…Despite numerous studies designed to improve treatment outcome, the median survival is only 3-6 months. [21] Diagnosis: Symptoms of brain metastases may be subtle initially, and may include headaches, nausea, vomiting, confusion, dizziness, decreased mental status, general or extremity weakness, urinary incontinence, gait disturbance, ataxia, visual disturbance including diplopia, photophobia, speech impairment, syncope or seizures [10,22].…”

“…than therapy of brain metastases with surgery alone, WBRT alone, chemotherapy alone, WBRT and chemotherapy, and no treatment (median survival of 6.7, 4.5, 7.5, 9.1, and 1.4 months, resp.). Thus, apparently, the best survival after diagnosis of brain metastases was achieved with multimodal therapy including surgical resection of the brain metastases followed by (whole brain radiotherapy) WBRT (± chemotherapy) or with SRS/GKRS [31].…”

Metastases to the brain and to the skull base of carcinomas that are rarely metastasize to the central nervous system. Clinical and morphological analysis of 51 cases and literature review

“…Медиана возраста пациенток в той работе была 58 лет, медиана выживаемости только при МГМ 3,9 месяцев, при наличии вместе с МГМ еще и экстракраниального пораже-ния -3,9 месяцев [14]. В целом, МГМ рака яичников отграничены небольшими сериями и отдельными описаниями случаев, коих в ли-тературе на конец 2011 года насчитывалось не более 600 [15]. Рак шейки матки обычно имеет местное распространение и чаще дает метастазы по лимфатическим путям в забрюшинные лимфа-тические узлы [9,13].…”